Evidence map›Paper›PMID 27494870›Full record

ArticleOncotarget2016

Novel antibody probes for the characterization of endosialin/TEM-1.

Daniel J O'Shannessy, Michael F Smith, Elizabeth B Somers, Stephen M Jackson, Earl Albone, Brian Tomkowicz, Xin Cheng, Young Park, Danielle Fernando, Andrew Milinichik and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniel J O'ShannessyMorphotek, Inc., Exton, PA, USA.
Michael F SmithMorphotek, Inc., Exton, PA, USA.
Elizabeth B SomersMorphotek, Inc., Exton, PA, USA.
Stephen M JacksonMorphotek, Inc., Exton, PA, USA.
Earl AlboneMorphotek, Inc., Exton, PA, USA.
Brian TomkowiczMorphotek, Inc., Exton, PA, USA.
Xin ChengMorphotek, Inc., Exton, PA, USA.
Young ParkMorphotek, Inc., Exton, PA, USA.
Danielle FernandoMorphotek, Inc., Exton, PA, USA.
Andrew MilinichikMorphotek, Inc., Exton, PA, USA.
Brad KlineMorphotek, Inc., Exton, PA, USA.
Regan FultonPhenoPath, Seattle, WA, USA.
Pankaj OberoiMeso Scale Discovery, Rockville, MD, USA.
Nicholas C NicolaidesMorphotek, Inc., Exton, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endosialin (Tumor Endothelial Marker-1 (TEM-1), CD248) is primarily expressed on pericytes of tumor-associated microvasculature, tumor-associated stromal cells and directly on tumors of mesenchymal origin, including sarcoma and melanoma. While the function of endosialin/TEM-1 is incompletely understood, studies have suggested a role in supporting tumor growth and invasion thus making it an attractive therapeutic target. In an effort to further understand its role in cancer, we previously developed a humanized anti-endosialin/TEM-1 monoclonal antibody (mAb), called ontuxizumab (MORAb-004) for testing in preclinical and clinical studies. We herein report on the generation of an extensive panel of recombinant endosialin/TEM-1 protein extracellular domain (ECD) fragments and novel mAbs against ECD motifs. The domain-specific epitopes were mapped against ECD sub-domains to identify those that can detect distinct structural motifs and can be potentially formatted as probes suitable for diagnostic and functional studies. A number of mAbS were shown to cross-react with the murine and human protein, potentially allowing their use in human animal models and corresponding clinical trials. In addition, pairing of several mAbs supported their use in immunoassays that can detect soluble endosialin/TEM-1 (sEND) in the serum of healthy subjects and cancer patients.

Indexed as

AnimalsAntibodies, MonoclonalAntibody SpecificityAntigens, CDAntigens, NeoplasmBinding SitesCHO CellsCricetinaeCricetulusCross ReactionsEpitopesHEK293 CellsHumansMiceNeoplasmsRats, Inbred LewAntibodies, MonoclonalAntigens, CDAntigens, NeoplasmCD248 protein, humanEpitopesRecombinant ProteinsCD248endosialinontuxizumabsENDTEM-1tumor microenvironment

Identifiers

PMID27494870
PMCPMC5342488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.